Simple non-invasive tests for fibrosis
| Score | Indices | Calculation | Interpretation |
|---|---|---|---|
| BARD score | BMI AST/ALT ratio T2DM | Weighted sum: 1. BMI ≥28=1 point 2. AAR ≥0.8=2 points 3. T2DM=1 point | Validated in 827 patients with biopsy proven NAFLD fibrosis47 Score ≥2: Se 0.91, Sp 0.66, NPV 0.96 AUROC 0.81 for stage 3–4 fibrosis |
| NAFLD fibrosis score | Age Hyperglycaemia BMI Platelet count Albumin AST/ALT ratio | −1.675+0.037×age (years)+0.094×BMI (kg/m2)+1.13×IFG or diabetes (yes=1, no=0)+0.99×AST/ALT ratio—0.013×platelet (×109/L)—0.66×albumin (g/dL) | Validated in 733 patients with NAFLD48 AUROC 0.88 for stage 3–4 fibrosis |
| FIB-4 score | Age AST ALT | Age×AST (IU/L)/platelet count (×109/L)×√ALT (IU/L) | Validated in 541 patients with biopsy-proven NAFLD AUROC 0.80 for stage 3–4 fibrosis49 |
AAR, AST/ALT ratio; AUROC, area under receiver operating characteristic; BMI, body mass index; IFG, impaired fasting glucose; NAFLD, non-alcoholic fatty liver disease; NPV, negative predictive value; Se, sensitivity; Sp, specificity; T2DM, type 2 diabetes mellitus.